An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study

Takuro Mizukami, Tempei Miyaji, Yukiya Narita, Tomohiro Matsushima, Takashi Ogura, Hiromichi Miyagaki, Ryohei Kawabata, Yoshiki Horie, Takashi Kawaguchi, Kei Muro, Hiroki Hara, Takuhiro Yamaguchi, Takako E Nakajima

Research output: Contribution to journalArticlepeer-review

Abstract

Limited data are available regarding the efficacy of nutrition support in advanced gastric cancer (AGC) patients receiving a standard second-line combination chemotherapy. The BALAST study is conducted as a prospective, multicenter observational study to evaluate the efficacy of nutrition support for patients with AGC treated with ramucirumab plus taxane as second-line treatment. As part of the routine care, patients who are malnourished or at risk of malnutrition will receive nutrition support from dietitians. We will enroll a total of 26 patients to estimate weight control rate at 12 weeks as primary end point. This study will generate valuable data reinforcing the role of nutrition support therapy for AGC patients receiving second-line chemotherapy.

Original languageEnglish
Pages (from-to)2431-2438
Number of pages8
JournalFuture Oncology
Volume17
Issue number19
DOIs
Publication statusPublished - 2021 Jul

Keywords

  • FAACT
  • PG-SGA
  • advanced gastric cancer
  • body weight loss
  • nutrition
  • nutrition counseling
  • taxane and ramucirumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study'. Together they form a unique fingerprint.

Cite this